Meyka Pro banner
Alvotech

Alvotech Fundamental Analysis (NASDAQ: ALVOW)

ALVOWNASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$0.22
$0.02(9.07%)
U.S. Market opens in 39h 41m

Alvotech Fundamental Analysis (NASDAQ: ALVOW)

Alvotech (NASDAQ: ALVOW) shows strong financial fundamentals with a PE ratio of -7.50, profit margin of -36.51%, and ROE of 76.83%. The company generates $0.4B in annual revenue with strong year-over-year growth of 19.74%.

Key Strengths

ROE76.83%
PEG Ratio0.08
Current Ratio1.65

Areas of Concern

Operating Margin9.62%
We analyze ALVOW's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 115.1/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.

Fundamental Health Score

A
115.1/100

We analyze ALVOW's fundamental strength across five key dimensions:

Efficiency Score

Weak

ALVOW struggles to generate sufficient returns from assets.

ROA > 10%
-11.31%

Valuation Score

Excellent

ALVOW trades at attractive valuation levels.

PE < 25
-7.50
PEG Ratio < 2
0.08

Growth Score

Moderate

ALVOW shows steady but slowing expansion.

Revenue Growth > 5%
19.74%
EPS Growth > 10%
1.11%

Financial Health Score

Excellent

ALVOW maintains a strong and stable balance sheet.

Debt/Equity < 1
-7.58
Current Ratio > 1
1.65

Profitability Score

Weak

ALVOW struggles to sustain strong margins.

ROE > 15%
76.83%
Net Margin ≥ 15%
-36.51%
Positive Free Cash Flow
No

Key Financial Metrics

Is ALVOW Expensive or Cheap?

P/E Ratio

ALVOW trades at -7.50 times earnings. This suggests potential undervaluation.

-7.50

PEG Ratio

When adjusting for growth, ALVOW's PEG of 0.08 indicates potential undervaluation.

0.08

Price to Book

The market values Alvotech at -8.17 times its book value. This may indicate undervaluation.

-8.17

EV/EBITDA

Enterprise value stands at -122.15 times EBITDA. This is generally considered low.

-122.15

How Well Does ALVOW Make Money?

Net Profit Margin

For every $100 in sales, Alvotech keeps $-36.51 as profit after all expenses.

-36.51%

Operating Margin

Core operations generate 9.62 in profit for every $100 in revenue, before interest and taxes.

9.62%

ROE

Management delivers $76.83 in profit for every $100 of shareholder equity.

76.83%

ROA

Alvotech generates $-11.31 in profit for every $100 in assets, demonstrating efficient asset deployment.

-11.31%

Following the Money - Real Cash Generation

Operating Cash Flow

Alvotech generates limited operating cash flow of $-174.25M, signaling weaker underlying cash strength.

$-174.25M

Free Cash Flow

Alvotech generates weak or negative free cash flow of $-263.29M, restricting financial flexibility.

$-263.29M

FCF Per Share

Each share generates $-0.84 in free cash annually.

$-0.84

FCF Yield

ALVOW converts -20.27% of its market value into free cash.

-20.27%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-7.50

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.08

vs 25 benchmark

P/B Ratio

Price to book value ratio

-8.17

vs 25 benchmark

P/S Ratio

Price to sales ratio

3.01

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-7.58

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.65

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.77

vs 25 benchmark

ROA

Return on assets percentage

-0.11

vs 25 benchmark

ROCE

Return on capital employed

0.04

vs 25 benchmark

How ALVOW Stacks Against Its Sector Peers

MetricALVOW ValueSector AveragePerformance
P/E Ratio-7.5030.97 Better (Cheaper)
ROE76.83%515.00% Weak
Net Margin-36.51%30197.00% Weak
Debt/Equity-7.580.53 Strong (Low Leverage)
Current Ratio1.655.71 Neutral
ROA-11.31%-16.00% (disorted) Weak

ALVOW outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Alvotech's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-1.48%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

101.84%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

92.44%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ